Time prior to the first measurable concentration after single and multiple doses of KVD824

Time of maximum observed concentration after single and multiple doses of KVD824 with and without food

Maximum observed concentration after single and multiple doses of KVD824 with and without food

Maximum observed concentration divided by dose

Plasma concentration observed at time 12 h after single and multiple doses

Plasma concentration observed at time 24 h after single and multiple doses

Concentration prior to the morning dose on Days 2-14 and prior to the evening dose on Days 2-13

Minimum observed concentration during the dosing interval (between dose time and dose time plus tau) after single and multiple doses of KVD824 with and without food

Average concentration (AUC(0-tau)/tau)

Area under the curve from time 0 to 12 hours post-dose after single and multiple doses

Area under the curve from time 0 to 12 hours post-dose divided by dose

Area under the curve from time 0 to 24 hours post-dose after single and multiple doses

Area under the curve from time 0 to 24 hours post-dose divided by dose

Area under the curve from time 0 to the time of last measurable concentration after single and multiple doses

Area under the curve from time 0 to the time of last measurable concentration divided by dose

Area under the curve for the defined interval between doses (tau)

Area under the curve from time 0 extrapolated to infinity

Area under the curve from time 0 extrapolated to infinity divided by dose

Area under the curve from time of the last measurable concentration to infinity as a percentage of the area under the curve extrapolated to infinity

Terminal elimination half-life after single and multiple doses of KVD824 with and without food

First order rate constant associated with the terminal (log-linear) portion of the curve after single and multiple doses

Total body clearance calculated after a single extravascular administration where F (fraction of dose bioavailable) is unknown

Total body clearance calculated using AUC(0-tau) after repeated extravascular administration, where F (fraction of dose bioavailable) is unknown

Apparent volume of distribution based on the terminal phase calculated using AUC(0-inf) after a single extravascular administration where F (fraction of dose bioavailable) is unknown

Apparent volume of distribution based on the terminal phase calculated using AUC(0-tau) after extravascular administration where F (fraction of dose bioavailable) is unknown

Relative bioavailability based on Cmax

Relative bioavailability based on AUC(0-12)

Relative bioavailability based on AUC(0-inf)

Accumulation ratio based on Cmax repeated dose/Cmax single dose

Peak to trough fluctuation (Cmax-Cmin)/Cavg × 100